Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monique Nilsson

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 5, 2020
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell CarcinomaJose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, et al.
Molecular Cancer Research : MCR|October 16, 2021
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-AdoAna Galan-Cobo, Christine M Stellrecht, Emrullah Yilmaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Cancers|July 27, 2022
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung AdenocarcinomaLingzhi Hong, Whitney E Lewis, Monique Nilsson, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic TargetXiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 5, 2020
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell CarcinomaJose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, et al.
Molecular Cancer Research : MCR|October 16, 2021
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-AdoAna Galan-Cobo, Christine M Stellrecht, Emrullah Yilmaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Cancers|July 27, 2022
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung AdenocarcinomaLingzhi Hong, Whitney E Lewis, Monique Nilsson, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic TargetXiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
Pageof 2